Friday, November 18, 2022 6:50:40 PM
This aged like milk. How's that priming for a big run up working out for you? Maybe someday people will realize the company is smoke and mirrors. Keep in mind your CEO is old as F, he dies... this thing tanks even harder.
Bearish
Recent ATOS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:25:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:25:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:24:42 PM
- Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer • PR Newswire (US) • 05/14/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 12:45:18 PM
- Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update • PR Newswire (US) • 05/08/2026 12:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 12:30:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 12:00:17 PM
- Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women • PR Newswire (US) • 05/06/2026 12:30:00 PM
- Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome • PR Newswire (US) • 05/04/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 12:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/30/2026 11:22:50 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/30/2026 09:33:51 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/30/2026 09:30:46 PM
- Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update • PR Newswire (US) • 03/25/2026 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/25/2026 09:21:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:20:21 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/20/2026 08:52:24 PM
- The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology • GlobeNewswire Inc. • 03/19/2026 03:00:00 PM
- Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives • PR Newswire (US) • 03/19/2026 12:00:00 PM
- Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference • PR Newswire (US) • 03/12/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 09:22:08 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/20/2026 09:16:05 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/20/2026 09:07:14 PM
